Skip to main content
NUFORMIX PLC logo

NUFORMIX PLC — Investor Relations & Filings

Ticker · NFX ISIN · GB00BYW79Y38 LEI · 2138003XG3H3I2J3BJ24 IL Professional, scientific and technical activities
Open in API
Filings indexed 279 across all filing types
Latest filing 2018-03-31 Annual Report
Country GB United Kingdom
Listing IL NFX

About NUFORMIX PLC

https://www.nuformix.com/

Nuformix PLC is a pharmaceutical development company focused on drug repurposing to address unmet medical needs, particularly in fibrosis and oncology. The company utilizes its expertise in cocrystal technology to unlock the therapeutic potential of approved drugs. This strategy involves creating new solid forms of existing medicines to improve their physical properties and performance, aiming to develop novel treatments with potentially accelerated development timelines.

Recent filings

Filing Released Lang Actions
Annual Report and AGM Notice
Annual Report Classification · 1% confidence The document is a comprehensive annual report for Nuformix plc for the 2017/18 fiscal year. It includes a Chairman's Statement, Strategic Report, Board of Directors information, Corporate Governance Report, Remuneration Report, Directors' Report, Independent Auditor's Report, and full Consolidated Financial Statements (Income Statement, Balance Sheet, Cash Flows, and Notes). This structure aligns perfectly with the definition of an Annual Report (10-K). FY 2018
2018-03-31 English
Proxy Form
Proxy Solicitation & Information Statement Classification · 1% confidence The document is explicitly titled "FORM OF PROXY" and pertains to the "NUFORMIX PLC —ANNUAL GENERAL MEETING". It contains instructions for appointing a proxy, voting on resolutions (including receiving the Annual Financial Report and approving remuneration policy), and deadlines for lodging the proxy form before the AGM date (September 19, 2018). This material is directly related to soliciting shareholder votes for the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R), as it is the primary material used for voting at the AGM, which is closely related to Proxy Solicitation (PSI), but AGM-R covers the meeting materials themselves, and PSI is usually the solicitation document sent prior to this form.
2018-03-31 English
Update re: Broker
Regulatory Filings Classification · 1% confidence The document is very short (2607 characters) and begins with an 'RNS Number' (5692G) and a date (02 March 2018). It discusses an update regarding the company's broker being placed into insolvency and the subsequent need to appoint a new broker. The text explicitly states, 'This information is provided by RNS The company news service from the London Stock Exchange' and ends with an RNS-specific identifier ('APPEADDAEAAPEFF'). This structure strongly indicates a general regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS), which corresponds to the 'Regulatory Filings' category, as it is not a specific financial report (like 10-K, IR, ER) or a specific corporate action announcement (like DIV, DIRS, CAP).
2018-03-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the header 'RNS Number : 0703G' and contains the standard structure of a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The key data points confirming this are the notification of 'An acquisition or disposal of voting rights' and the table detailing 'Total positions of person(s) subject to the notification obligation' showing percentage changes (e.g., 17.04%). This aligns perfectly with the definition for Major Shareholding Notification (MRQ).
2018-02-27 English
NXP002 Pilot Study in Lung and Liver Fibrosis
Earnings Release Classification · 1% confidence The document begins with an 'RNS Number' and the date '31 January 2018', indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details positive results from a pilot study for a drug program (NXP002) and includes a disclaimer about distribution restrictions typical of market-sensitive news. While it contains financial/operational updates, its primary function, as indicated by the RNS header and the nature of the announcement (a positive study outcome release), aligns best with a general regulatory filing or announcement. Since it is not a full report (like 10-K or IR), nor a specific announcement like a dividend (DIV) or management change (MANG), the most appropriate classification is the general regulatory filing category, RNS, as it is explicitly branded as an RNS release. FY 2018
2018-01-31 English
NXP002 Pilot Study in Lung and Liver Fibrosis
Earnings Release Classification · 1% confidence The document is an announcement dated January 31, 2018, detailing positive pilot study results for a drug candidate (NXP002) in treating lung and liver fibrosis. It summarizes key findings, quotes the CEO, and provides background on the disease and the company's technology. This content structure—a press release announcing scientific/clinical progress and business updates—is characteristic of an Earnings Release (ER) or a general business update. Since it focuses purely on R&D results and does not appear to be a full quarterly/interim financial report (IR) or a formal Annual Report (10-K), the most appropriate classification is Earnings Release (ER), as these announcements often accompany or precede formal earnings reports to highlight operational achievements. It is not a Call Transcript (CT), a Director's Dealing (DIRS), or a Dividend Notice (DIV). It is a substantive announcement, not just a notice of publication (RPA). FY 2018
2018-01-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.